EHA HIGHLIGHTS 2024 – LYMPHOMA ROUNDTABLE DISCUSSION: ECHO TRIAL
OR
Chair
Dr. Robert Kridel
Panelists
Dr. Kerry Savage
Dr. Diego Villa
This program has been made possible through unrestricted support from Roche.
Studies/trials discussed:
- ECHO trial
- Mosunetuzumab demonstartes clinically meaningful outcomes in high-risk patients with heavily pretreated, relapsed/refractory follicular lymphoma after three or more years of follow up.
